Literature DB >> 11456313

Potassium channel antibodies in two patients with reversible limbic encephalitis.

C Buckley1, J Oger, L Clover, E Tüzün, K Carpenter, M Jackson, A Vincent.   

Abstract

Limbic encephalitis (LE) is often associated with lung, thymic, or testicular tumours and antibodies to Hu, CV2, or Ma2 (Ta) antigens. In these cases, it generally has a poor prognosis. Here we describe two patients with symptoms of LE, negative for typical paraneoplastic antibodies, in whom antibodies to voltage-gated potassium channels (VGKC) were detected retrospectively in serial serum samples. Patient 1 had a thymoma recurrence, but in patient 2 no tumour has been detected in the years following presentation. Plasma exchange was effective in reducing VGKC antibody levels, with substantial improvement in mental symptoms in patient 1. In patient 2, the VGKC antibodies fell spontaneously over two years, with almost complete recovery of mental function. Although neither patient had obvious neuromyotonia at presentation, both showed excessive secretions. We suggest that patients with limbic symptoms and excessive secretions should be tested for VGKC antibodies, and, if they are present, prompt and effective immunosuppressive treatment should be considered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456313     DOI: 10.1002/ana.1097

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  93 in total

Review 1.  Paraneoplastic neurologic syndromes.

Authors:  Steven Vernino
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Unusual association of seronegative, nonparaneoplastic limbic encephalitis and relapsing polychondritis in a patient with history of thymectomy for myasthenia: a case study.

Authors:  Kateřina Storey; Radoslav Matěj; Robert Rusina
Journal:  J Neurol       Date:  2010-08-13       Impact factor: 4.849

Review 3.  [Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture].

Authors:  H Prüss; J Dalmau; V Arolt; K-P Wandinger
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

4.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.

Authors:  Meizan Lai; Maartje G M Huijbers; Eric Lancaster; Francesc Graus; Luis Bataller; Rita Balice-Gordon; John K Cowell; Josep Dalmau
Journal:  Lancet Neurol       Date:  2010-06-28       Impact factor: 44.182

5.  Autoimmune encephalopathy presenting as a 'posterior circulation stroke'.

Authors:  H Kearney; B Murray; E Kavanagh; K O'Rourke; P Kelly; T Lynch
Journal:  J Neurol       Date:  2010-09-24       Impact factor: 4.849

Review 6.  Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies.

Authors:  Emilia H Moscato; Ankit Jain; Xiaoyu Peng; Ethan G Hughes; Josep Dalmau; Rita J Balice-Gordon
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

Review 7.  Infections, inflammation and epilepsy.

Authors:  Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher
Journal:  Acta Neuropathol       Date:  2015-09-30       Impact factor: 17.088

8.  Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders.

Authors:  Josep Dalmau; Luis Bataller
Journal:  Hematol Oncol Clin North Am       Date:  2006-12       Impact factor: 3.722

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

10.  Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease.

Authors:  Michael D Geschwind; K Meng Tan; Vanda A Lennon; Ramon F Barajas; Aissa Haman; Christopher J Klein; S Andrew Josephson; Sean J Pittock
Journal:  Arch Neurol       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.